Screener
BioMarin Pharmaceuticals BMRN EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's EBITDA margin?
- BioMarin Pharmaceuticals (BMRN) reported EBITDA margin of 10.3% in Q2 2026.
- How has BioMarin Pharmaceuticals's EBITDA margin changed year-over-year?
- BioMarin Pharmaceuticals's EBITDA margin decreased by 63.4% year-over-year, from 28% to 10.3%.
- What is the long-term trend for BioMarin Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's EBITDA margin has grown at a 38.1% compound annual growth rate (CAGR), from 3.3% to 16.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about BioMarin Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude